Table 1.
Various universal Influenza vaccines in clinical trials.
| Immunogen | Vaccine Name /Platform |
Identifier | Manufacturer | Phase | Status | Effect | Adjuvant |
|---|---|---|---|---|---|---|---|
| HA | Chimeric HA-based LAIV combinations | NCT03300050 | Icahn School of Medicine at Mount Sinai (US) | 1 | Completed | Induces high anti-stalk Ab titers and long-lasting immunity | AS03A |
| M2e | M2e-based VLPs | NCT00819013 | Ghent Univ (Belgium) Sanofi Pasteur (US) |
1 | Completed | Induces anti-M2e Ab | Alum and QS-21 |
| RedeeFlu M2SR/M2e-deficient |
NCT03999554 NCT02822105 NCT03553940 NCT04785794 |
Flugen, Inc. (US) | 1 1 1 1 |
Completed Completed Completed Ongoing |
Reduces symptom scores and virus replication | None | |
| NP and M1 | MVA−NP+M1/Viral vector |
NCT00942071 NCT00993083 NCT01465035 NCT01818362 NCT02014168 NCT03277456 NCT03300362 NCT03883113 NCT03880474 |
Vaccitech Ltd. | 1 2 1 1 1 1 2 2 2 |
Completed Completed Completed Completed Terminated Completed Completed Completed Terminated |
Reduces influenza symptoms and length of virus shedding, induces T cell responses |
None |
| ChAdOx1 NP+M1/Adenoviral vector | NCT01623518 | Jenner Institute, University of Oxford | 1 | Completed | Increases T cell response | None | |
| NP | OVX836/Reco-mbinant NP | NCT04192500 NCT03594890 | Osivax SAS (France) | 2 1 |
Completed Completed |
None yet reported | None |
| HA, NP, and M1 | M-001/ Recombinant protein |
NCT01010737 NCT01146119 NCT01419925 NCT02293317 NCT02691130 NCT03058692 NCT03450915 |
BiondVax Pharmaceuticals Ltd. (Israel) | 1/2 2 2 2 2 2 3 |
Completed Completed Completed Completed Completed Completed Completed |
Induces significant cellular-mediated immunity and HI titers | Montanide ISA-51/ Oil –in-water |
| NP, M1, P1, and P2 | FP-01.1/ Peptide based |
NCT01265914 NCT01677676 NCT01701752 NCT02071329 |
Immune Targeting Systems Ltd. (United Kingdom) | 1 1 1 1/2 |
Completed Completed Completed Completed |
Good safety and tolerability profiles | None |
| NP, M1, and M2 | FLU-v/ Peptide based |
NCT01181336 NCT01226758 NCT03180801 NCT02962908 |
PepTcell (SEEK, United Kingdom) | 1 1 2 2 |
Completed Completed Completed Completed |
Stimulates cell-mediated immunity, reduces symptomatology and virus shedding | Montanide ISA-51/Oil –in-water |